Neurotechnology Wins Fisheries-Focused Computer Vision Competition – findBIOMETRICS

Posted on June 14, 2017

Neurotechnology researchers have won first place in a competition designed to find AI solutions for fisheries monitoring.

The competition was organized by Kaggle, an online crowdsourcing platform aimed at the tech and research communities. Organized by The Nature Conservancy and aimed ultimately at applying sophisticated computer vision technology to the fight to protect global fisheries from overfishing and other threats, the Nature Conservancy Fisheries Monitoring competition essentially asked participants to develop algorithms that could automatically detect and identify different species of fish and other marine life.

A group composed entirely of members of Neurotechnologys AI development team, working under the team name TROLL (Towards Robust Optimal Learning of Learning), beat 2,292 other teams to take the companys $50,000 first prize with their algorithm solution.

Its extracurricular as far as Neurotechnologys business goes, but the Kaggle win highlights the talent at work in the company, which recently announced a new version of its MegaMatcher Accelerator platform, which Neurotechnology says is now the fastest biometric engine in the world.

June 14, 2017 by Alex Perala

Excerpt from:

Neurotechnology Wins Fisheries-Focused Computer Vision Competition - findBIOMETRICS

Neurotechnology Researchers Win Kaggle Competition with Deep Neural Network Solution for The Nature … – PR Newswire (press release)

The Fisheries Monitoring competition was one of the biggest Kaggle competitions. According to The Nature Conservancy, which initiated this competition, illegal, unreported and unregulated fishing practices are threatening marine ecosystems, global seafood supplies and local livelihoods. By using computer technology to aid in monitoring fisheries, human capital can be re-allocated to management and enforcement, helping local, regional and global partners preserve the integrity and viability of these fisheries today and into the future.

2,293 teams submitted algorithms for the identification of fish and other marine species from video streams. Competing solutions were evaluated based on an unseen test set that resembles a real-life scenario.

The Neurotechnology employees, who entered the competition independently under the team name "Towards Robust-Optimal Learning of Learning," used state-of-the-art deep neural networks to solve the problem and provide the best overall solution in the competition. The winning team is comprised of Gediminas Peksys, Ignas Namajunas and Jonas Bialopetravicius, all of whom work on Neurotechnology's AI development team, which designs and delivers a range of products and services based on deep neural networks, including computer vision and object recognition.

"This was one of the first Kaggle competitions that was comprised of two stages, which means that models developed during the first stage were frozen and evaluated on unseen data that was made available during the second stage," said Gediminas Peksys from the Towards Robust Optimal Learning of Learning team. "In such a setting, it is very easy for a team's models to overfit the data by using too many trainable parameters. We were able to utilize our team's experience using deep neural networks to come up with a robust model that performed a lot closer to the original estimate from stage one and generalized in a predictable manner on unseen data."

"We congratulate our employees who won this difficult competition," said Dr. Algimantas Malickas, owner of Neurotechnology. "These individuals along with many other excellent employees working on our client projects demonstrate the qualifications of our Neurotechnology staff and their ability to solve the most complex pattern recognition and neural network training problems."

About Neurotechnology

Neurotechnology is a developer of high-precision algorithms and software based on deep neural network (DNN) and other AI-related technologies. The company offers a range of products for biometric fingerprint, face, iris, palmprint and voice identification as well as AI, computer vision, object recognition and robotics. Drawing from years of academic research in the fields of neuroinformatics, image processing and pattern recognition, Neurotechnology was founded in 1990 in Vilnius, Lithuania and released its first fingerprint identification system in 1991. Since that time the company has released more than 130 products and version upgrades. More than 3000 system integrators, security companies and hardware providers integrate Neurotechnology's algorithms into their products, with millions of customer installations worldwide. Neurotechnology's algorithms also achieved top results in independent technology evaluations including NIST MINEX and IREX.

Media ContactJennifer Allen Newton Bluehouse Consulting Group, Inc. +1-503-805-7540 jennifer (at) bluehousecg (dot) com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurotechnology-researchers-win-kaggle-competition-with-deep-neural-network-solution-for-the-nature-conservancy-fisheries-monitoring-300473515.html

SOURCE Neurotechnology

http://www.neurotechnology.com

Read the rest here:

Neurotechnology Researchers Win Kaggle Competition with Deep Neural Network Solution for The Nature ... - PR Newswire (press release)

Neurotechnology Releases MegaMatcher Accelerator Extreme, the Fastest Biometric Engine in the World – PR Newswire (press release)

MegaMatcher Accelerator Extreme edition includes enhanced functionality and reliability compared to the previous MegaMatcher Accelerator version, with more fingerprint, face and eye iris capabilities and significantly faster speeds. It provides bigger capacity, handling up to 160 million fingerprints, up to 40 million faces and up to 200 million eye iris templates on single server.

Neurotechnology is offering a simple upgrade path into the Extreme edition from other MegaMatcher Accelerator editions for the existing customers.

MegaMatcher Accelerator is available through Neurotechnology or from distributors worldwide. For more information and trial version, go to: http://www.neurotechnology.com.

About Neurotechnology

Neurotechnology is a developer of high-precision algorithms and software based on deep neural network (DNN) and other AI-related technologies. The company offers a range of products for biometric fingerprint, face, iris, palmprint and voice identification as well as AI, computer vision, object recognition and robotics. Drawing from years of academic research in the fields of neuroinformatics, image processing and pattern recognition, Neurotechnology was founded in 1990 in Vilnius, Lithuania and released its first fingerprint identification system in 1991. Since that time the company has released more than 130 products and version upgrades. More than 3000 system integrators, security companies and hardware providers integrate Neurotechnology's algorithms into their products, with millions of customer installations worldwide. Neurotechnology's algorithms also received top results in independent technology evaluations such as NIST MINEX and IREX.

Media ContactJennifer Allen Newton Bluehouse Consulting Group, Inc. +1-503-805-7540 jennifer (at) bluehousecg (dot) com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurotechnology-releases-megamatcher-accelerator-extreme-the-fastest-biometric-engine-in-the-world-300472075.html

SOURCE Neurotechnology

http://www.neurotechnology.com

The rest is here:

Neurotechnology Releases MegaMatcher Accelerator Extreme, the Fastest Biometric Engine in the World - PR Newswire (press release)

Neurotech panel shares successes from first year – Cornell Chronicle

Faculty from Cornell Neurotech shared stories of technologies and tools they have developed in their first year of operation at a Reunion 2017 panel, Unlocking the Brain: Cornells Search for the Key.

University Photography

Arts and Sciences Dean Gretchen Ritter '83, Engineering Dean Lance Collins and Stephen Mong '92, MBA 02, MEN 93, take in the panel discussion June 9.

The June 9 discussion featured Joseph Fetcho, director of Cornell Neurotech and professor in the Department of Neurobiology and Behavior; and Chris Xu, M.S. 93, Ph.D. 96, the Mong Family Foundation Director of Cornell Neurotech and a professor in the Department of Applied and Engineering Physics.

In the first year alone, Cornell Neurotech is already realizing many newfound research collaborations, said Gretchen Ritter 83, the Harold Tanner Dean of Arts and Sciences. These multidisciplinary partnerships have developed several key advances in our understanding of the brain and in the tools we can use to further decode its mysteries.

Cornell Neurotech a joint initiative of the College of Engineering and the College of Arts and Sciences launched with a multimillion dollar seed grant from the Mong Family Foundation, through Stephen Mong 92, MBA 02, MEN 93. The initiative aims to build tools that enable scientists to better understand and treat disorders such as Alzheimers disease, Parkinsons disease, autism, epilepsy, schizophrenia and depression.

Fetcho brought the presentation to a personal level by sharing videos of his mother, who no longer recognizes her children. He said research into diseases like hers needs to answer questions such as: Have the nerve cells in his mothers brain died? If not, where are they? Have their connections been damaged? Has the pattern of activity in the brain changed?

To find the answers, scientists are developing tools to look deep into the brain with high-resolution imagery, to look at neurons as they fire, as they search for connections, as they gain and lose synapses and to try to connect that brain activity to various behaviors and conditions, he said.

Fetchos lab does brain research using young zebrafish, whose transparency is a huge advantage in viewing brain activity.

Transferring this research from transparent fish to mammals has been one of the challenges given to Xu, who is developing tools and techniques that see deep into the brains of mice and can image several different regions of the brain at the same time.

Our Laboratory for Innovative Neurotechnology at Cornell is using technology to enable answers to currently impossible neuroscience questions, Xu said.

Along with support for labs and research, one feature of Cornell Neurotech is the Mong Fellowship Program, which pairs life scientist postdocs with postdocs in engineering, physics or chemistry to work together on a pressing problem.

We havent solved the brain yet, but we have done some remarkable things with respect to tools to understand it, Fetcho said of the first years progress.

Lance Collins, the Joseph Silbert Dean of Engineering, said the neurotech initiative began, and will continue to grow, because of the natural curiosity and collaboration of Cornell faculty.

This idea nucleated through interactions happening within the faculty and was taken to the next level by an outstanding alumni gift, Collins said. Faculty did this because they were genuinely and intrinsically interested in the problem, so they brought their expertise together. Thats how we do it here.

Kathy Hovis is a writer for the College of Arts and Sciences.

Read more from the original source:

Neurotech panel shares successes from first year - Cornell Chronicle

Comparing Stryker Corporation (SYK) & Accuray (ARAY) – Markets Daily

Comparing Stryker Corporation (SYK) & Accuray (ARAY)
Markets Daily
The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other.

and more »

The rest is here:

Comparing Stryker Corporation (SYK) & Accuray (ARAY) - Markets Daily

Neurotechnology Announces MegaMatcher Accelerator Extreme … – findBIOMETRICS

Posted on June 12, 2017

Neurotechnology has announced a new version of its MegaMatcher Accelerator biometric software platform that enables faster matching than ever.

Its called MegaMatcher Accelerator Extreme, and Neurotechnology says that on a single server it can match 700 million irises per second, 1.2 billion faces per second, and 1.2 billion fingerprints per second. It can also manage 200 million iris templates, 40 million faces, and 160 million fingerprint templates on one server.

In a statement announcing the new platform, Neurotechnology called it the fastest biometric engine in the world, with the companys Director Irmantas Naujikas asserting that it will allow our customersto implement large and complex solutions in a simpler way, utilizing considerably fewer servers than before and simplifying system deployment and maintenance.

MegaMatcher Accelerator Extreme arrives soon after Neurotechnology announced an upgraded version of its SentiVeillance facial recognition SDK, which can now scan up to ten different surveillance feeds on a single computer.

June 12, 2017 by Alex Perala

Read more from the original source:

Neurotechnology Announces MegaMatcher Accelerator Extreme ... - findBIOMETRICS

Head to Head Analysis: Accuray (ARAY) and Stryker Corporation (SYK) – Sports Perspectives


Sports Perspectives
Head to Head Analysis: Accuray (ARAY) and Stryker Corporation (SYK)
Sports Perspectives
The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other.
Stryker Corporation (SYK)Zacks.com

all 68 news articles »

Continue reading here:

Head to Head Analysis: Accuray (ARAY) and Stryker Corporation (SYK) - Sports Perspectives

Welch Capital Partners Increased By $3.59 Million Its Eqt (EQT) Position, Stryker (SYK) Sellers Decreased By 3.59 … – UtahHerald.com

June 7, 2017 - By Hazel Jackson

Stryker Corporation (NYSE:SYK) had a decrease of 3.59% in short interest. SYKs SI was 4.88M shares in June as released by FINRA. Its down 3.59% from 5.06M shares previously. With 925,900 avg volume, 5 days are for Stryker Corporation (NYSE:SYK)s short sellers to cover SYKs short positions. The SI to Stryker Corporations float is 1.49%. It closed at $144.05 lastly. It is down 24.95% since June 7, 2016 and is uptrending. It has outperformed by 8.25% the S&P500.

Welch Capital Partners Llc increased Eqt Corp (EQT) stake by 67.55% reported in 2016Q4 SEC filing. Welch Capital Partners Llc acquired 55,210 shares as Eqt Corp (EQT)s stock declined 9.10%. The Welch Capital Partners Llc holds 136,943 shares with $8.96M value, up from 81,733 last quarter. Eqt Corp now has $9.39B valuation. It closed at $53.97 lastly. It is down 18.61% since June 7, 2016 and is downtrending. It has underperformed by 35.31% the S&P500.

Stryker Corporation is a medical technology company. The company has market cap of $53.78 billion. The Firm offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. It has a 32.32 P/E ratio. The Companys divisions include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other.

Among 19 analysts covering Stryker Corporation (NYSE:SYK), 12 have Buy rating, 3 Sell and 4 Hold. Therefore 63% are positive. Stryker Corporation had 34 analyst reports since July 27, 2015 according to SRatingsIntel. The stock of Stryker Corporation (NYSE:SYK) has Market Perform rating given on Tuesday, November 1 by BMO Capital Markets. The stock of Stryker Corporation (NYSE:SYK) has Buy rating given on Thursday, December 15 by UBS. Argus Research maintained Stryker Corporation (NYSE:SYK) rating on Wednesday, April 27. Argus Research has Buy rating and $130 target. BMO Capital Markets downgraded the stock to Underperform rating in Monday, December 14 report. As per Friday, March 3, the company rating was maintained by RBC Capital Markets. RBC Capital Markets maintained Stryker Corporation (NYSE:SYK) rating on Wednesday, April 26. RBC Capital Markets has Outperform rating and $140 target. Needham downgraded the stock to Underperform rating in Friday, January 6 report. Barclays Capital initiated the shares of SYK in report on Monday, April 11 with Underweight rating. The rating was maintained by Canaccord Genuity on Wednesday, January 25 with Buy. The company was upgraded on Wednesday, April 27 by Sterne Agee CRT.

Investors sentiment increased to 0.86 in 2016 Q4. Its up 0.07, from 0.79 in 2016Q3. It increased, as 50 investors sold Stryker Corporation shares while 331 reduced holdings. 72 funds opened positions while 257 raised stakes. 277.34 million shares or 0.00% more from 277.33 million shares in 2016Q3 were reported. Savings Bank Of Montreal Can holds 0.02% or 192,296 shares in its portfolio. Rand Wealth Ltd Com reported 13,720 shares. Polar Llp holds 180,000 shares or 0.34% of its portfolio. Hall Laurie J Trustee owns 34,992 shares. 1,745 are held by Dorsey Whitney Trust Ltd. Caz Investments Limited Partnership has 1.87% invested in Stryker Corporation (NYSE:SYK) for 13,270 shares. 8,484 were reported by South Texas Money. Private State Bank Trust has 4,073 shares for 0.07% of their portfolio. Inv Services Of America Inc reported 2.26% of its portfolio in Stryker Corporation (NYSE:SYK). Next Gp Inc invested 0% in Stryker Corporation (NYSE:SYK). Saturna Cap Corporation holds 1.26% in Stryker Corporation (NYSE:SYK) or 300,000 shares. Cantab Capital Partners Limited Liability Partnership invested 0% of its portfolio in Stryker Corporation (NYSE:SYK). Family Mgmt owns 0.16% invested in Stryker Corporation (NYSE:SYK) for 2,000 shares. National Pension Ser accumulated 0.2% or 244,754 shares. Massachusetts Services Com Ma accumulated 0.67% or 11.45M shares.

Since December 9, 2016, it had 1 insider buy, and 10 sales for $13.28 million activity. FRANCESCONI LOUISE sold $454,623 worth of Stryker Corporation (NYSE:SYK) on Monday, January 30. 5,194 shares were sold by STRYKER RONDA E, worth $626,410. Lobo Kevin sold $1.30M worth of stock or 9,539 shares. Another trade for 13,322 shares valued at $1.81M was made by Scannell Timothy J on Monday, May 1. $1.40M worth of Stryker Corporation (NYSE:SYK) shares were sold by Becker Yin C. 41 shares were bought by Doliveux Roch, worth $5,048.

Welch Capital Partners Llc decreased Bright Horizons Family Solutions Inc (NYSE:BFAM) stake by 59,776 shares to 61,273 valued at $4.29M in 2016Q4. It also reduced Surgical Care Affiliates Inc. (NASDAQ:SCAI) stake by 20,830 shares and now owns 71,333 shares. Gentex Corp (NASDAQ:GNTX) was reduced too.

Since January 1, 2017, it had 2 buys, and 1 insider sale for $157,693 activity. Cary A. Bray Jr. had bought 417 shares worth $27,272 on Sunday, January 1. Another trade for 3,479 shares valued at $210,688 was sold by Hyland M Elise.

Among 20 analysts covering EQT Corporation (NYSE:EQT), 9 have Buy rating, 0 Sell and 11 Hold. Therefore 45% are positive. EQT Corporation had 43 analyst reports since July 21, 2015 according to SRatingsIntel. The company was maintained on Friday, June 2 by RBC Capital Markets. The firm has Hold rating by Tudor Pickering given on Thursday, October 13. On Tuesday, July 21 the stock rating was initiated by Cowen & Co with Outperform. The firm has Buy rating given on Wednesday, February 3 by GMP Securities. The stock has Buy rating by Stifel Nicolaus on Friday, August 26. The stock of EQT Corporation (NYSE:EQT) earned Hold rating by Jefferies on Tuesday, January 12. The stock of EQT Corporation (NYSE:EQT) has Hold rating given on Friday, April 7 by Jefferies. As per Friday, December 9, the company rating was downgraded by Seaport Global. As per Monday, October 24, the company rating was initiated by Credit Suisse. The stock of EQT Corporation (NYSE:EQT) has Accumulate rating given on Wednesday, January 13 by Seaport Global.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Read the rest here:

Welch Capital Partners Increased By $3.59 Million Its Eqt (EQT) Position, Stryker (SYK) Sellers Decreased By 3.59 ... - UtahHerald.com

Comparing Accuray (ARAY) & Stryker (SYK) – The Cerbat Gem

Comparing Accuray (ARAY) & Stryker (SYK)
The Cerbat Gem
The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other.

and more »

View post:

Comparing Accuray (ARAY) & Stryker (SYK) - The Cerbat Gem

Shoosmiths advises PD Neurotechnology on 1.34m (EUR) investment – Shoosmiths legal updates (press release)

Published: 06 Jun 2017

Author: Robyn Adams

National law firm Shoosmiths has advised P D Neurotechnology (PDN) on its 1.34m (EUR) funding for the development of its ground breaking wearable medical technology.

PDN has received funding of 1,000,000 (EUR)from the founders and angel investors with a follow-on funding commitment of 340,000 (EUR)from the National Bank of Greece (NBG), 1.34m (EUR)in total. The funding will see the continued development of PDN's wearable medical technology for continuous monitoring and treating of movement disorders which is anticipated to assist in the treatment of chronic diseases like Parkinson's disease.

Shoosmiths' corporate partner Stuart Murray and solicitor Alexander Lamley advised PDN on the UK legal aspects of receiving the funding that involved a complicated structural arrangement to deal with exchange controls and NBG investment criteria.

Nikolaos Moschos, President of the board directors at PDN, commented: 'This funding will ensure the continued development of our innovative wearable medical technology that will significantly benefit sufferers of debilitating movement disorders and illnesses such as Parkinson's disease. The team at Shoosmiths has provided effective, commercial advice with an efficient and proactive service that has ensured the timely securing of this funding.'

Stuart Murray added: 'We are extremely pleased to have assisted PDN on this significant investment into the development of their innovative medical product and wish them all the best for the future.' Shoosmiths' corporate team advises public and private companies, management teams, investors and debt providers through the business life cycle. Shoosmiths work with businesses from start-up and first round finance through to mergers and acquisitions, MBO and MBI transactions, development funding and on exits, by way of sale, listing or private equity investment.

Nationally, the corporate team is ranked in first place by deal volume in Experian's 2016 MarketIQ UK & Ireland M&A league tables. The team was recognised for its mergers and acquisitions expertise at the 2015 M&A Awards, winning the Law Firm of the Year category.

Read more:

Shoosmiths advises PD Neurotechnology on 1.34m (EUR) investment - Shoosmiths legal updates (press release)

Shoosmiths advises PD Neurotechnology on 1.34m investment – Scottish Legal News

Stuart Murray

Shoosmiths has advised P D Neurotechnology (PDN) on its 1.34 million funding for the development of itswearable medical technology.

PDN has received funding of 1m from the founders and angel investors with a follow-on funding commitment of 340,000 from the National Bank of Greece (NBG), 1.34m in total. The funding will see the continued development of PDNs wearable medical technology for continuous monitoring and treating of movement disorders which is anticipated to assist in the treatment of chronic diseases like Parkinsons disease.

Shoosmiths corporate partner Stuart Murrayand solicitor Alexander Lamley advised PDN on the UK legal aspects of receiving the funding that involved a complicated structural arrangement to deal with exchange controls and NBG investment criteria.

Nikolaos Moschos, president of the board directors at PDN, said: This funding will ensure the continued development of our innovative wearable medical technology that will significantly benefit sufferers of debilitating movement disorders and illnesses such as Parkinsons disease. The team at Shoosmiths has provided effective, commercial advice with an efficient and proactive service that has ensured the timely securing of this funding.

Mr Murray added: We are extremely pleased to have assisted PDN on this significant investment into the development of their innovative medical product and wish them all the best for the future.

deals, shoosmiths June 6, 2017

Originally posted here:

Shoosmiths advises PD Neurotechnology on 1.34m investment - Scottish Legal News

Positive Media Coverage Very Likely to Affect Stryker (SYK) Share Price – Chaffey Breeze


Transcript Daily
Positive Media Coverage Very Likely to Affect Stryker (SYK) Share Price
Chaffey Breeze
The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company's segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other.
Stryker Corporation (SYK) Surges to 52-Week High, Is Now Top ...KL Daily

all 21 news articles »

Read more here:

Positive Media Coverage Very Likely to Affect Stryker (SYK) Share Price - Chaffey Breeze

How Neurotechnology Is Helping The San Francisco Giants Train Better – PSFK (subscription)

Halo Neuroscience's headset ensures practice has a bigger impact on the brain and the body

San Francisco-based neurotechnology company Halo Neuroscience has partnered with the San Francisco Giants. After reviewing research and testing the Halo Sport headset, they have now officially incorporated it into every players core training.

During testing, athletes were split into two groups to complete 20-minute warm-ups followed by 60 minutes of focused training to improve skill, speed, and power. Those in one group wore Halo Sport headsets during the 20-minute warm-up. This group saw the greatest improvements in speed work. In a 20-yard dash, almost all the athletes tested demonstrated significant improvement after two weeks, versus athletes in the control group who only demonstrated modest improvement.

Using Halo Sport means that every rep a baseball player puts in during practice has a bigger impact on their brain and body. When a player is at bat, his muscle memory has better recall of all past swings in the batting cage. For a pitcher, the form theyve perfected in training is replicated more precisely on the mound. When a player who has been training for explosivity is on base, they can launch more efficiently because their muscles know how to respond. Training with Halo Sport has been shown to accelerate improvement in bat velocity, grip strength, and speed.

As a result of these findings, the Giants will continue to implement Halo Sport to improve movement-based training for its athletes.

Dave Groeschner, Head Athletic Trainer for the San Francisco Giants, said in a press release:

We are extremely excited to integrate Halos neurostimulation technology into our core training regimen to improve and refine on-field player performance and athleticism. After testing the product internally, weve determined that incorporating Halo Sport Neuropriming into our training programs produces measurable and significant results.

You can learn more about Halo Sport in the video below:

Halo Neuroscience

Go here to read the rest:

How Neurotechnology Is Helping The San Francisco Giants Train Better - PSFK (subscription)

Elon Musk Wants to Merge Man and MachineHere’s What He’ll … – Observer

Computers and brains already talk to each other daily in high-tech labs and they do it better and better. For example, disabled people can now learn to govern robotic limbs by the sheer power of their mind. The hope is that we may one day be able to operate spaceships with our thoughts, upload our brains to computers and, ultimately, create cyborgs.

Now Elon Musk is joining the race. The CEO of Tesla and SpaceX has acquired Neuralink, a company aiming to establish a direct link between the mind and the computer. Musk has already shown how expensive space technology can be run as a private enterprise. But just how feasible is his latest endeavour?

Neurotechnology was born in the 1970s when Jaques Vidal proposed that electroencephalography (EEG), which tracks and records brain-wave patterns via sensors placed on the scalp (electrodes), could be used to create systems that allow people to control external devices directly with their mind. The idea was to use computer algorithms to transform the recorded EEG signals into commands. Since then, interest in the idea has been growing rapidly.

Indeed, these brain-computer interfaces have driven a revolution in the area of assistive technologies letting people with quadriplegia feed themselves and even walk again. In the past few years, major investments in brain research from the US (the BRAIN initiative) and the EU (the Human Brain project) have further advanced research on them. This has pushed applications of this technology into the area of human augmentation using the technology to improve our cognition and other abilities.

The combination of humans and technology could be more powerful than artificial intelligence. For example, when we make decisions based on a combination of perception and reasoning, neurotechnologies could be used to augment our perception. This could help us in situations such when seeing a very blurry image from a security camera and having to decide whether to intervene or not.

Despite investments, the transition from using the technology in research labs to everyday life is still slow. The EEG hardware is totally safe for the user, but records very noisy signals. Also, research labs have been mainly focused on using it to understand the brain and to propose innovative applications without any follow-up in commercial products. Other very promising initiatives, such as using commercial EEG systems to let people drive a car with their thoughts, have remained isolated.

To try to overcome some of these limitations, several major companies have recently announced investments in research into brain-computer interfaces. Bryan Johnson from human intelligence company Kernel recently acquired the MIT spin-off firm KRS, which is promising to make a data-driven revolution in understanding neurodegenerative diseases. Facebook is hiring a brain-computer interface engineer to work in its secretive hardware division, Building 8.

Musks company is the latest. Its neural lace technology involves implanting electrodes in the brain to measure signals. This would allow getting neural signals of much better quality than EEG but it requires surgery. The project is still quite mysterious, although Musk has promised more details about it soon. Last year he stated that brain-computer interfaces are needed to confirm humans supremacy over artificial intelligence.

The project might seem ambitious, considering the limits of current technology. BCI spellers, which allow people to spell out words by looking at letters on a screen, are still much slower than traditional communication means, which Musk has already defined as incredibly slow. Similar speed limitations apply when using the brain to control a video game.

What we really need to make the technology reliable is more accurate, non-invasive techniques to measure brain activity. We also need to improve our understanding of the brain processes and how to decode them. Indeed, the idea of uploading or downloading our thoughts to or from a computer is simply impossible with our current knowledge of the human brain. Many processes related to memory are still not understood by neuroscientists. The most optimistic forecasts say it will be at least 20 years before brain-computer interfaces will become technologies that we use in our daily lives.

But that doesnt make Musks initiative useless. The neural lace could initially be used to study the brain mechanisms and treat disorders such as epilepsy or major depression. Together with electrodes for reading the brain activity, we could also implant electrodes for stimulating the brain making it possible to detect and halt epileptic seizures.

Brain-computer interfaces also face major ethical issues, especially those based on sensors surgically implanted in the brain. Most people are unlikely to want to have brain surgery or be fit to have it unless vital for their health. This could significantly limit the number of potential users of Musks neural lace. Kernels original idea when acquiring the company KRS was also to implant electrodes in peoples brain, but the company changed its plans six months later due to difficulties related to invasive technologies.

Its easy for billionaires like Musk to be optimistic about the development of brain-computer interfaces. But, rather than dismissing them, lets remember that these visions are nevertheless crucial. They push the boundaries and help researchers set long-term goals.

Theres every reason to be optimistic. Neurotechnology started only started a few years after man first set foot on the moon perhaps reflecting the need for a new big challenge after such a giant leap for mankind. And the brain-computer interfaces were indeed pure science fiction at the time.

In 1965, the Sunday comic strip Our New Age stated:

By 2016, mans intelligence and intellect will be able to be increased by drugs and by linking human brains directly to computers!

We are not there yet, but together we can win the challenge.

Davide Valeriani, is a post-doctoral Researcher in Brain-Computer Interfaces at theUniversity of Essex. This article was originally published on The Conversation. Read the original article.

Read the original:

Elon Musk Wants to Merge Man and MachineHere's What He'll ... - Observer

Synchron Inc. Secures $10 Million in Series A Financing Round – PR Newswire (press release)

"We have designed a product to attempt to overcome the greatest challenge facing other neural interfaces: chronic brain tissue scarring," said Thomas Oxley, MD, PhD, founder and CEO of Synchron.

"We aim to provide a safe way for patients with severe paralysis to achieve direct brain control of assistive devices. Successful completion of this funding round allows us to commence human studies."

The Stentrode system is small and flexible enough to safely pass through curving blood vessels in a procedure called cerebral angiography, eliminating the need for open brain surgery and direct contact with brain tissue. By using blood vessels to deliver the technology to the brain and house it there, the technique may reduce risk of brain tissue rejection of the device, which has been a significant problem for other techniques.

Pre-clinical studies published in Nature Biotechnology have demonstrated the Stentrode's ability to pick up high-frequency electrical data emitted by the brain. This level of brain recording has previously required invasive electrode implantation through the skull.

According to a global report from McKinsey & Co., in advanced economies, there are 50 million people with impaired mobility due to paralysis. A new industry of 'robotic human augmentation' promises to provide novel solutions to patients with paralysis to achieve enhanced and independent control of their environment.

The Stentrode was initially developed through a multi-departmental collaboration at the University of Melbourne, The Florey Institute of Neuroscience and Mental Health, and the Royal Melbourne Hospital, Australia. The Australian company SmartStent was spun out in 2012 and was wholly acquired by Silicon Valley-based Synchron in 2016. Early funding for the device was provided from the U.S. Department of Defense, including DARPA and theU.S. Office of Naval Research Global.

Dr. Oxley and Nicholas Opie, PhD, Synchron co-founder and chief technology officer, also received substantial funding from the Australian National Medical Health and Medical Research Council (NHMRC) to the University of Melbourne Vascular Bionics Laboratory to develop the technology.

About Synchron, Inc.Based in Silicon Valley, Synchron, Inc. is an innovative medical device company focused on the development of minimally invasive neuromodulation technology solutions. Synchron is developing the world's first endovascular neural interface, the StentrodeTM. Development of this technology platform has been funded in part by grants from the U.S. Defense Advanced Research Projects Agency (DARPA) and U.S. Department of Defense (DoD). The company is targeting paralysis due to a range of neurological conditions as a first application. Other applications may include epilepsy and movement disorders.

Stentrode is a trademark of Synchron, Inc.

About NTI Neurotechnology Investors (http://themdadvantage.com ) draws on the knowledge and investment power of over 100 neurology, neurosurgery and radiology specialists from across the U.S. to perform targeted investments in high potential technologies.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/synchron-inc-secures-10-million-in-series-a-financing-round-300433942.html

SOURCE Synchron Inc.

http://www.synchronmed.com

Original post:

Synchron Inc. Secures $10 Million in Series A Financing Round - PR Newswire (press release)

Stryker’s Spine division to exhibit key technologies at AAOS 2017 – OrthoSpineNews

Share this story with your network

ALLENDALE, N.J.(BUSINESS WIRE)Strykers Spine division today announced that it will demonstrate its Aero-C Cervical Stability System (Aero-C) and Xia 4.5 Cortical Trajectory implants and instruments (Xia CT) at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 1518, 2017, in San Diego (booth No. 3133).

Aero-C, the only straight forward anterior cervical discectomy and fusion (ACDF) device that offers uniform compression across the interbody space, will be displayed at AAOS 2017, highlighting its full commercial launch. Using Aerofoil Compression Technology, Aero-C is designed to pull the vertebral bodies toward the implant as it is inserted, creating compressive forces at the implant-to-endplate interface.1 Aerofoil Compression Technology is also available for lateral and anterior lumbar interbody fusion procedures (LLIF and ALIF). Since the initial introduction to the market, over 600 cases have been completed.

Also to be demonstrated at AAOS is Xia CT, which includes implants and instruments used in less invasive LITe LIF posterior lumbar interbody fusion procedures for patients with degenerative disc disease, spondylolisthesis, and trauma. The cortical trajectory procedure facilitates a smaller midline incision to help achieve decompression, fixation, and fusion.2 It also is intended to be more muscle sparing than standard open procedures that require lateral dissection, and its reduced incision may allow for more efficient exposure and closure time.2 The launch of the Xia CT system occurred in 2016, with 575 cases completed to date.

Since their introduction last year, Aero-C and Xia CT have been well received by our surgeon customers and have achieved rapid adoption in the marketplace, said Bradley Paddock, President of Strykers Spine division. These unique products reflect our strong commitment to advancing spine health and helping to enhance outcomes for patients by providing physicians with innovative and differentiated technology.

Aero-C and Xia CT offer advancements that highlight the Spine divisions leadership in pioneering innovative technologies for traditional and minimally invasive surgical techniques. The company offers one of the most comprehensive and diverse product portfolios for the treatment of degenerative and complex spinal disorders. Its suite of leading-edge products includes implants, instruments, and biologics for the cervical, thoracic, and lumbar spine.

About Stryker

Stryker is one of the worlds leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information atwww.stryker.com.

References

Indications for Use

The AERO-C Cervical Cage is indicated for use in cervical interbody fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one level from the C2-C3 disc to the C7-T1 disc. The AERO-C Cervical Cage System is to be used with autogenous bone graft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft, and is to be implanted via an open, anterior approach.

The Xia CT implants and instruments are intended for anterior/anterolateral and posterior, non-cervical pedicle and non-pedicle fixation for the following indications: Degenerative Disc Disease (as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies); spondylolisthesis; trauma (i.e. fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis, and/or lordosis); tumor; pseudarthrosis; failed previous fusion.

Content ID: CVAER-PR-2_13458

See the original post here:

Stryker's Spine division to exhibit key technologies at AAOS 2017 - OrthoSpineNews

Preview: MedX Future of Healthcare conference – The Mancunion

Photo: ReThinkX

The MedX Future of Healthcare conference will be held on 25th March at Citylabs 1.0, ran by ReThinkX, which aims to bridge the gap between the next generation and leaders of the field and to create an accessible medium to showcase the technology at the forefront of healthcare.

Tariq Ramtoola, Director of ReThinkX, says: We will have speaker panels running in the same time as workshops in order for people to feel more free to choose what mood they are in: listening to innovative speakers, be more hands on, be enthusiastic and debate, or even just relax in the chill-out area. There will be something for everybody!

We think traditional conferences are too rigid and set the agenda for attendees, says Ramtoola on the format of the conference.

Keynotes on the day include Hugo Mercier, CEO & co-founder of Rythm, a neurotechnology company that has made the first active wearable headband to help improve sleep. The Dreem headband is due to be available to consumers soon.

Also speaking is Dr Pablo Rojo, a Paediatric Infectious Diseases Specialist from Madrid. Previously Dr Rojo is part of the EPIICAL project, which aims to provide new therapeutics to early treated HIV-infected children, and has published over 80 peer-reviewed articles in his career.

Unlike other events of its kind, the MedX conference is free for students, but limited priced tickets are available for academics and professionals in the healthcare field. Explaining this decision, Ramtoola says that ReThinkX wanted to put great emphasis on accessibility.

Workshops will also be held throughout the day, including one by GMC which will challenge the ethical implications of social media and a digital world, led by Tista Chakravarty-Gannon, GMCs Principal Regional Liaison Advisor.

Bella Eacott, Research and Curriculum Manager at Clod Ensemble, and Suzy Wilson, Director of Performing Medicine, an education programme led by a theatre company will be holding a Circle of Care workshop, looking at art based methods in healthcare education.

In the future, ReThinkX hope to grow the conference so that it spans two days with 500 to 1000 delegates.

We are working with Manchester entrepreneurs, Manchester Science Partnerships and the North-West Biotech Initiative to create an entrepreneurship academy focused on small scale innovation, Ramtoola says.

Tickets are available here.

The rest is here:

Preview: MedX Future of Healthcare conference - The Mancunion

How to ensure future brain technologies will help and not harm society – USAPP American Politics and Policy (blog)

Thomas Edison, one of the great minds of the second industrial revolution, once said that the chief function of the body is to carry the brain around. Understanding the human brain how it works, and how it is afflicted by diseases and disorders is an important frontier in science and society today.

Advances in neuroscience and technology increasingly impact intellectual wellbeing, education, business, and social norms. Recent findings confirm the plasticity of the brain over the individuals life. Imaging technologies and brain stimulation technologies are opening up totally new approaches in treating disease and potentially augmenting cognitive capacity. Unravelling the brains many secrets will have profound societal implications that require a closer contract between science and society.

Convergence across physical science, engineering, biological science, social science and humanities has boosted innovation in brain science and technological innovation. It offers large potential for a systems biology approach to unify heterogeneous data from omics tools, imaging technologies such as fMRI, and behavioural science.

Citizen science the convergence between science and society already proved successful in EyeWire where people competed to map the 1,000-neuron connectome of the mouse retina. Also, the use of nanoparticles as coating of implanted abiotic devices offers great potential to improve the immunologic acceptance of invasive diagnostics. Brain-inspired neuromorphic engineering aims to develop novel computer systems with brain-like characteristics, including low energy consumption, adequate fault tolerance, self-learning capabilities, and some sort of intelligence. Here, the convergence of nanotechnology with neuroscience could help building neuro-inspired computer chips; brain-machine interfaces and robots with artificial intelligence systems.

Future opportunities for cognitive enhancement for improved attentiveness, memory, decision making, and control through, for example, non-invasive brain stimulation and neural implants have raised, and shall continue to raise, profound ethical, legal, and social questions. What is societally acceptable and desirable, both now and in the future?

At a recent OECD workshop, we identified five possible systemic changes that could help speed up neurotechnology developments to meet pressing health challenges and societal needs.

There is growing interest in discussing and unpacking the ethical and societal aspects of brain science as the technologies and applications are developed. Much can be learned from other experiences in disruptive innovation. The international Human Genome Project (1990-2003), for example, was one of the earlier large-scale initiatives in which social scientists worked in parallel with the natural sciences in order to consider the ethical, legal and social issues (ELSI) of their work.

The deliberation of ELSI and Responsible Research and Innovation (RRI) in nanotechnologies is another example of how societies, in some jurisdictions, have approached R&D activities, and the role of the public in shaping, or at least informing, their trajectory. RRI knits together activities that previously seemed sporadic. According to Jack Stilgoe, Senior Lecturer in the Department of Science and Technology Studies, University College London, the aim of responsible innovation is to connect the practice of research and innovation in the present to the futures that it promises.

Frameworks, such as ELSI and RRI should more actively engage patients and patient organisations early in the development cycle, and in a meaningful way. This could be achieved through continuous public platforms and policy discussion instead of traditional one-off public engagement and the deliberation of scientific advances and ELSI through culture and art.

Research funders public agencies, private investors, foundations, as well as universities themselves are particularly well positioned to shape trajectories of technology and society. Through their funding power, they have unique capacity to help place scientific work within social, ethical, and regulatory contexts.

It is an opportune time for funders to: 1) strengthen the array of approaches and mechanisms for building a robust and meaningful neurotechnology landscape that meaningfully engages human values and is informed by it; 2) discuss options to foster open and responsible innovation; and 3) better understand the opportunities and challenges for building joint initiatives in research and product development.

Society and industry would benefit from earlier, and more inclusive, discussions about the ethical, legal and social implications of how neurotechnologies are being developed and their entry onto the market. For example, the impact of neuromodulatory devices that promise to enhance cognition, alter mood, or improve physical performance on human dignity, privacy, and equitable access could be considered earlier in the research and development process.

Given the significant investment risks and high failure rates of clinical trials in central nervous systems disorders, companies could adopt more open innovation approaches in which public and private stakeholders actively collaborate, share assets including intellectual property, and invest together.

Popular media is full of colourful brain images used to illustrate stories about neuroscience. Unproven health claims, including those which give rise to so-called neuro-hype and neuro-myths. Misinformation is a strong possibility where scientific work potentially carries major social implications (for example, work on mental illness, competency, intelligence, etc).

It has the potential to result in public mistrust and to undermine the formation of markets. There is a need for evidence-based policies and guidelines to help the responsible development and use of neurotechnology in medical practice and in over-the-counter products. Policymakers and regulators could lead the development of a clear path to translate neurotechnology discoveries into human health advantages that are commercially viable and sustainable.

Policymakers should discuss the socio-economic questions raised by neurotechnology. Rising disparities in access to often high-priced medical innovation require tailored solutions for poorer countries. The development of public-private partnerships and simplification of technology help access to innovation in resource-limited countries.

In addition to helping people with neurological and psychiatric disorders, the biggest cause of disability worldwide, neurotechnologies will shape every aspect of society in the future. A roadmap for guiding responsible research and innovation in neurotechnology may be transformative.

Notes:

P. Murali Doraiswamy Leading expert in brain and behavioural sciences, health innovation and mobile medical technologies. Professor of Psychiatry and Medicine, Duke University Health System. Member of corporate and non-profit boards. Adviser to several health and technology businesses.

Hermann GardenOrganisation for Economic Co-operation and Development, Working Party on Biotechnology, Nanotechnology and Converging Technologies

David WinickoffOrganisation for Economic Co-operation and Development, Working Party on Biotechnology, Nanotechnology and Converging Technologies

Go here to see the original:

How to ensure future brain technologies will help and not harm society - USAPP American Politics and Policy (blog)

Stryker Corporation named one of Fortune Magazine’s 100 Best Companies to Work For for seventh consecutive year – Yahoo Finance

Kalamazoo, Michigan - March 9, 2017 - Stryker Corporation (SYK) announced today that it has been named one of Fortune`s 2017 100 Best Companies to Work For in its 20th annual survey of top-rated workplaces in the United States. The list recognizes companies that have exceptional workplace cultures. This is the seventh consecutive year Stryker has been named to the list, and the company was ranked #19 out of 100. The full list and related stories are available at http://beta.fortune.com/best-companies/.

"We are thrilled once again to be named to Fortune`s 100 Best Companies to Work For," said Katy Fink, Vice President, Chief Human Resources Officer. "This recognition speaks to what makes us special-it`s about the people! We are honored to work with great people who are driven, ethical, caring and humble. They live our mission and values every day, and they are the reason that Stryker is one of the best places to work."

Stryker is one of the world`s leading medical technology companies and,together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services inOrthopaedics, Medical and Surgical,and Neurotechnology and Spine that help improvepatient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information atwww.stryker.com.

Stryker is one of the world`s leading medical technology companies and,together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services inOrthopaedics, Medical and Surgical,and Neurotechnology and Spine that help improvepatient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information atwww.stryker.com.

Contacts

For investor inquiries please contact: Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com

For media inquiries please contact: Yin Becker, Stryker Corporation, 269-385-2600 or yin.becker@stryker.com

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Stryker Corporation via GlobeNewswire HUG#2086600

Read more:

Stryker Corporation named one of Fortune Magazine's 100 Best Companies to Work For for seventh consecutive year - Yahoo Finance

Stryker’s Spine division to exhibit key technologies at AAOS 2017 – Yahoo Finance

ALLENDALE, N.J.--(BUSINESS WIRE)--

Strykers Spine division today announced that it will demonstrate its Aero-C Cervical Stability System (Aero-C) and Xia 4.5 Cortical Trajectory implants and instruments (Xia CT) at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, March 1518, 2017, in San Diego (booth No. 3133).

Aero-C, the only straight forward anterior cervical discectomy and fusion (ACDF) device that offers uniform compression across the interbody space, will be displayed at AAOS 2017, highlighting its full commercial launch. Using Aerofoil Compression Technology, Aero-C is designed to pull the vertebral bodies toward the implant as it is inserted, creating compressive forces at the implant-to-endplate interface.1 Aerofoil Compression Technology is also available for lateral and anterior lumbar interbody fusion procedures (LLIF and ALIF). Since the initial introduction to the market, over 600 cases have been completed.

Also to be demonstrated at AAOS is Xia CT, which includes implants and instruments used in less invasive LITe LIF posterior lumbar interbody fusion procedures for patients with degenerative disc disease, spondylolisthesis, and trauma. The cortical trajectory procedure facilitates a smaller midline incision to help achieve decompression, fixation, and fusion.2 It also is intended to be more muscle sparing than standard open procedures that require lateral dissection, and its reduced incision may allow for more efficient exposure and closure time.2 The launch of the Xia CT system occurred in 2016, with 575 cases completed to date.

Since their introduction last year, Aero-C and Xia CT have been well received by our surgeon customers and have achieved rapid adoption in the marketplace, said Bradley Paddock, President of Strykers Spine division. These unique products reflect our strong commitment to advancing spine health and helping to enhance outcomes for patients by providing physicians with innovative and differentiated technology.

Aero-C and Xia CT offer advancements that highlight the Spine divisions leadership in pioneering innovative technologies for traditional and minimally invasive surgical techniques. The company offers one of the most comprehensive and diverse product portfolios for the treatment of degenerative and complex spinal disorders. Its suite of leading-edge products includes implants, instruments, and biologics for the cervical, thoracic, and lumbar spine.

About Stryker

Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. The Company offers a diverse array of innovative products and services in Orthopaedics, Medical and Surgical, and Neurotechnology and Spine that help improve patient and hospital outcomes. Stryker is active in over 100 countries around the world. Please contact us for more information atwww.stryker.com.

References

Indications for Use

The AERO-C Cervical Cage is indicated for use in cervical interbody fusion procedures in skeletally mature patients with degenerative disc disease (DDD) at one level from the C2-C3 disc to the C7-T1 disc. The AERO-C Cervical Cage System is to be used with autogenous bone graft and/or allogenic bone graft comprised of cancellous and/or corticocancellous bone graft, and is to be implanted via an open, anterior approach.

The Xia CT implants and instruments are intended for anterior/anterolateral and posterior, non-cervical pedicle and non-pedicle fixation for the following indications: Degenerative Disc Disease (as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies); spondylolisthesis; trauma (i.e. fracture or dislocation); spinal stenosis; curvatures (i.e., scoliosis, kyphosis, and/or lordosis); tumor; pseudarthrosis; failed previous fusion.

Content ID: CVAER-PR-2_13458

View source version on businesswire.com: http://www.businesswire.com/news/home/20170309005195/en/

More:

Stryker's Spine division to exhibit key technologies at AAOS 2017 - Yahoo Finance